US FDA Allows Zyn Nicotine Pouches to Be Marketed as Reduced-Risk

The U.S. Food and Drug Administration granted Philip Morris permission to market Zyn nicotine pouches as a reduced-risk alternative to cigarettes ^[1].

This decision marks a significant shift in how nicotine products are labeled in the U.S. market. By allowing a "less harmful" claim, the regulator acknowledges a tiered risk system for nicotine delivery, potentially influencing the choices of millions of adult smokers.

The FDA based its decision on a scientific review of the product's constituents ^[1]. The agency determined that the pouches expose users to lower levels of harmful substances compared to combustible tobacco ^[1].

"The FDA's decision is based on a thorough review of the scientific evidence showing that Zyn nicotine pouches expose users to lower levels of harmful constituents than cigarettes," an FDA spokesperson said ^[1].

Medical experts suggest the ruling provides a pathway for those who cannot quit nicotine entirely. Dr. Payal Kohli said Zyn offers a reduced-risk alternative for adult smokers who are unable or unwilling to quit nicotine altogether ^[3].

However, the ruling has drawn scrutiny from public health advocates. Critics argue that the label of reduced risk could be misinterpreted as a general endorsement of safety. One public health critic said that while the claim of reduced risk is now allowed, it does not mean Zyn is safe for everyone, especially youth ^[1].

The FDA's authorization is specifically targeted toward adult smokers. The goal is to provide a product that delivers nicotine with a lower health risk than the act of smoking combustible cigarettes [1, 2].